Azacitidine
Adult Acute Myeloblastic Leukemia
Stanford UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Acute Myeloblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cc-5013 Stanford University | Phase 1/2 | CCC |
DEXAMETHASONE Stanford University | Phase 1/2 | CCC |
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →